# A Clinical Study of Hetrombopag Olamine Tablets in Adults Receiving 21-day Cycles of Chemotherapy for Solid Tumours, Who Are Delayed for at Least 1 Week From Their Scheduled Cycle Because of Chemotherapy-induced Thrombocytopenia

> **NCT05261646** · PHASE3 · WITHDRAWN · sponsor: **Jiangsu HengRui Medicine Co., Ltd.**

## Conditions studied

- Chemotherapy-Induced Thrombocytopenia

## Interventions

- **DRUG:** Hetrombopag
- **DRUG:** Matching placebo

## Key facts

- **NCT ID:** NCT05261646
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-04-15
- **Primary completion:** 2025-03-15
- **Final completion:** 2025-12-15
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor R \& D Strategy Adjustment
- **Last updated:** 2023-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05261646

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05261646, "A Clinical Study of Hetrombopag Olamine Tablets in Adults Receiving 21-day Cycles of Chemotherapy for Solid Tumours, Who Are Delayed for at Least 1 Week From Their Scheduled Cycle Because of Chemotherapy-induced Thrombocytopenia". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05261646. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*